Needham analyst Michael Matson has maintained their bullish stance on MMSI stock, giving a Buy rating on March 28.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Michael Matson has given his Buy rating due to a combination of factors discussed during the fireside chat at the Needham Healthcare Conference. One of the key reasons is Merit Medical Systems’ strategic positioning in the market, which includes their exposure to tariffs and operations in China, suggesting a robust international presence.
Additionally, the company’s focus on innovative products like WRAPSODY and its clear financial targets contribute to a positive outlook. Matson also considers the potential for mergers and acquisitions as a growth strategy, which further supports the Buy rating. These elements together indicate a strong potential for future growth and profitability for Merit Medical Systems.
In another report released on March 28, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $120.00 price target.